Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vectus Biosystems Limited ( (AU:VBS) ) has shared an update.
Vectus Biosystems has moved closer to monetising part of its pipeline, nearing completion of a binding deal to sell its VB4-P5 renal small molecule compound for renal fibrosis to Canadian biotech XORTX Therapeutics for US$3 million in shares and pre-funded warrants, giving Vectus a strategic equity stake in a Nasdaq- and TSX Venture-listed renal drug developer. The company, which has sharply reduced operating costs and ended the December 2025 quarter with A$330,000 in cash, is intensifying efforts to secure licensing and funding partnerships for its anti-fibrotic portfolio, including VB0004, with active outreach via C14 Consulting, data room access for potential licensees, a particular push into the Chinese market for Phase IIa trials in liver and lung disease, and exploration of future capital options including eventual sales of XORTX equity once escrow restrictions lift.
The most recent analyst rating on (AU:VBS) stock is a Hold with a A$0.12 price target. To see the full list of analyst forecasts on Vectus Biosystems Limited stock, see the AU:VBS Stock Forecast page.
More about Vectus Biosystems Limited
Vectus Biosystems Limited is an Australian biotechnology company focused on developing anti-fibrotic therapies for major diseases affecting the heart, kidney and liver. Its lead orally doseable small molecule, VB0004, targets tissue fibrosis and high blood pressure and has completed Phase Ia and Ib human trials, supported by a broader patented drug library aimed at making its early-stage assets attractive to larger pharmaceutical partners.
Average Trading Volume: 96,863
Technical Sentiment Signal: Hold
Current Market Cap: A$6.95M
For detailed information about VBS stock, go to TipRanks’ Stock Analysis page.